The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors
作者单位:Samsung Med Ctr, Samsung Canc Res Inst, Samsung Biomed Res Inst, Seoul, South Korea[1]Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Dept Med, Seoul 135710, South Korea[2]